Margetuximab: An active alternative for later-line therapy in patients with HER2-positive advanced breast cancer

被引：1
|
作者：
Zhou, Yunxiang [1 ,2 ]
Wang, Xiaojia [3 ]
Chen, Yiding [1 ,2 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Breast Surg & Oncol, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Canc Inst,Key Lab Canc Prevent & Intervent,China N, Hangzhou, Zhejiang, Peoples R China
[3] Chinese Acad Sci, Univ Chinese Acad Sci, Inst Basic Med & Canc IBMC, Dept Breast Med Oncol,Canc Hosp,Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
来源：
MEDCOMM | 2023年 / 4卷 / 04期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1002/mco2.322
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Margetuximab for HER2-Positive Breast Cancer
    Cuellar, Sandra
    ONCOLOGY-NEW YORK, 2021, 35 (09): : 573 - 575
  • [2] Margetuximab in HER2-positive metastatic breast cancer
    Gradishar, William J.
    O'Regan, Ruth
    Rimawi, Mothaffar F.
    Nordstrom, Jeffrey L.
    Rosales, Minori K.
    Rugo, Hope S.
    FUTURE ONCOLOGY, 2023, 19 (16) : 1099 - 1112
  • [3] Margetuximab for the treatment of HER2-positive metastatic breast cancer
    Tarantino, Paolo
    Morganti, Stefania
    Uliano, Jacopo
    Giugliano, Federica
    Crimini, Edoardo
    Curigliano, Giuseppe
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (02) : 127 - 133
  • [4] Effectiveness of third- or later-line therapy in patients with HER2-positive advanced gastric cancer: Results from an observational retrospective study in Japan
    Omori, Takeshi
    Sakai, Daisuke
    Fumita, Soichi
    Fujita, Junya
    Kawabata, Ryohei
    Matsuyama, Jin
    Yasui, Hisateru
    Hirao, Motohiro
    Kawase, Tomono
    Kishi, Kentaro
    Taniguchi, Hirokazu
    Miyazaki, Yasuhiro
    Miura, Tomoko
    Miyake, Akimitsu
    Kurokawa, Yukinori
    Yamasaki, Makoto
    Yamada, Tomomi
    Satoh, Taroh
    Eguchi, Hidetoshi
    Doki, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [5] A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer
    Alasmari, Moudi M.
    CANCERS, 2023, 15 (01)
  • [6] FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer
    Royce, Melanie
    Osgood, Christy L.
    Amatya, Anup K.
    Fiero, Mallorie H.
    Chang, C. J. George
    Ricks, Tiffany K.
    Shetty, Krithika A.
    Kraft, Jeffrey
    Qiu, Junshan
    Song, Pengfei
    Charlab, Rosane
    Yu, Jingyu
    King, Kathryn E.
    Rastogi, Anshu
    Janelsins, Brian
    Weinberg, Wendy C.
    Clouse, Kathleen
    Borders-Hemphill, Vicky
    Brown, Lindsey
    Gomez-Broughton, Candace
    Li, Zhong
    Thuy Thanh Nguyen
    Qiu, Zhihao
    Anh-Thy Ly
    Chang, Suyoung
    Gao, Tingting
    Tu, Chi-Ming
    King-Kallimanis, Bellinda
    Pierce, William F.
    Chiang, Kelly
    Lee, Clara
    Goldberg, Kirsten B.
    Leighton, John K.
    Tang, Shenghui
    Pazdur, Richard
    Beaver, Julia A.
    Amiri-Kordestani, Laleh
    CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1487 - 1492
  • [7] HER2-positive advanced breast cancer
    Robert, Nicholas J.
    Favret, Anne M.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 21 (02) : 293 - +
  • [8] First-line therapy of advanced HER2-positive breast carcinoma
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (01) : 14 - 14
  • [9] Pyrotinib for Elderly Patients with Advanced HER2-Positive Breast Cancer
    Li, Yan
    Ma, Xiaoping
    Zhao, Zhenhui
    Li, Li
    Gao, Chunyan
    Liu, Dan
    Li, Bingyu
    Zhao, Bing
    BREAST CANCER-TARGETS AND THERAPY, 2022, 14 : 405 - 415
  • [10] Activity of Fulvestrant in patients with HER2-positive advanced breast cancer
    Robertson, J. F. R.
    Steger, G.
    Neven, P.
    Barni, S.
    Kaufman, B.
    Gieseking, F.
    EJC SUPPLEMENTS, 2007, 5 (04): : 222 - 222
12345